Veeva Systems Inc. $VEEV Shares Purchased by Goodman Advisory Group LLC

Goodman Advisory Group LLC increased its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 189.3% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 22,243 shares of the technology company’s stock after purchasing an additional 14,554 shares during the period. Veeva Systems makes up approximately 2.2% of Goodman Advisory Group LLC’s investment portfolio, making the stock its 15th largest position. Goodman Advisory Group LLC’s holdings in Veeva Systems were worth $6,406,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sigma Planning Corp lifted its stake in Veeva Systems by 1.2% during the second quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock worth $958,000 after purchasing an additional 39 shares in the last quarter. Keybank National Association OH raised its holdings in shares of Veeva Systems by 1.4% in the 2nd quarter. Keybank National Association OH now owns 3,088 shares of the technology company’s stock valued at $889,000 after buying an additional 42 shares during the period. Facet Wealth Inc. lifted its stake in Veeva Systems by 3.3% during the 2nd quarter. Facet Wealth Inc. now owns 1,342 shares of the technology company’s stock worth $381,000 after acquiring an additional 43 shares in the last quarter. TFB Advisors LLC lifted its stake in Veeva Systems by 1.2% during the 1st quarter. TFB Advisors LLC now owns 3,586 shares of the technology company’s stock worth $831,000 after acquiring an additional 44 shares in the last quarter. Finally, Triangle Securities Wealth Management boosted its holdings in Veeva Systems by 0.8% during the 2nd quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock valued at $1,665,000 after acquiring an additional 45 shares during the period. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Veeva Systems Stock Down 2.9%

NYSE VEEV opened at $222.87 on Friday. Veeva Systems Inc. has a 52 week low of $201.54 and a 52 week high of $310.50. The firm has a 50 day moving average of $273.45 and a two-hundred day moving average of $278.69. The stock has a market capitalization of $36.63 billion, a PE ratio of 43.36, a price-to-earnings-growth ratio of 1.66 and a beta of 1.05.

Veeva Systems (NYSE:VEEV) last announced its quarterly earnings data on Thursday, November 20th. The technology company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. The business had revenue of $0.81 million for the quarter, compared to analyst estimates of $792.37 million. Veeva Systems had a net margin of 27.93% and a return on equity of 13.68%. The company’s revenue was up 16.0% on a year-over-year basis. During the same period last year, the business earned $1.75 EPS. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. On average, equities research analysts expect that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Jonathan Faddis sold 720 shares of the company’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $298.12, for a total transaction of $214,646.40. Following the completion of the transaction, the senior vice president directly owned 7,868 shares of the company’s stock, valued at approximately $2,345,608.16. This represents a 8.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Thomas D. Schwenger sold 3,350 shares of the stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total value of $1,005,134.00. Following the completion of the transaction, the insider owned 23,773 shares in the company, valued at approximately $7,132,850.92. The trade was a 12.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 24,665 shares of company stock valued at $7,438,000 in the last ninety days. Insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Wells Fargo & Company cut their price target on shares of Veeva Systems from $341.00 to $333.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 25th. Needham & Company LLC reissued a “buy” rating and issued a $355.00 price objective on shares of Veeva Systems in a research note on Friday, November 21st. Piper Sandler upped their target price on shares of Veeva Systems from $325.00 to $355.00 and gave the stock an “overweight” rating in a research note on Thursday, August 28th. Raymond James Financial reiterated an “outperform” rating and set a $340.00 target price (up from $310.00) on shares of Veeva Systems in a report on Thursday, August 28th. Finally, Stifel Nicolaus raised their price target on shares of Veeva Systems from $295.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Eighteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $307.42.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.